GERN news

Latest 3 stories · newest Nov 4, 2026

GERN

Geron Q3 revenue beats forecast on strong RYTELO demand, initiates EU launch

Geron reported $60.1M net product revenue, up 10% QoQ, and reiterated a high-end revenue guidance of $240M. The company announced a gated commercial launch in European markets to expand patient access.

Earnings Nov 4, 2026 sentiment +0.70 SEC filing ↗

GERN

Geron discontinues Phase 3 trial of imetelstat in myelofibrosis due to DMC recommendation

Geron halted the Phase 3 IMpactMF trial of imetelstat in JAK inhibitor relapsed/refractory myelofibrosis following Data Monitoring Committee advice, although the company remains committed to its commercial RYTELO business.

Regulatory Oct 28, 2026 sentiment -0.60 SEC filing ↗

GERN

Geron reports Q2 2026 revenue of $57.5M on RYTELO

Geron delivered $57.5 million in RYTELO net product revenue for the second quarter of 2026, increasing net revenue by 24% year-over-year amid lowered operating expenses.

Earnings Aug 6, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same GERN feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/GERN/newsSTART FREE